TScan Therapeutics, Inc.
TCRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, TScan Therapeutics, Inc. (TCRX) is listed under Biotechnology. The $61.5M market capitalization puts TCRX squarely in micro-cap range for its industry. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Market Cap
$61.5M
Beta
1.04
P/E (TTM)
—
P/E (Fwd)
-1.06
EPS (TTM)
$-0.98
EPS (Fwd)
$-0.89
ROE
-81.0%
ROA
-29.6%
Cash
$128.1M
Total Debt
$92.5M
Free CF
-$84.1M
52W Change
-49.2%
Annual Financials
Cash vs Debt
Where TCRX stands vs its 150-day and 200-day moving averages
As of the July 9, 2026 close, TCRX finished 18.87% above its 150-day moving average ($1.06) and 3.28% above its 200-day moving average ($1.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TCRX overbought or oversold?
At the July 9, 2026 close, TCRX's RSI(14) was 78.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $128.1M in cash and $92.5M in debt, TCRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$84.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -81.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $13.5M to $10.3M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TCRX.